Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Subscribe To Our Newsletter & Stay Updated
